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Abstract 
 
Sequence changes in regulatory regions have often been invoked to explain phenotypic 
divergence among species, but molecular examples of this have been difficult to obtain.  In this 
study, we identified an anthropoid primate specific sequence element that contributed to the 
regulatory evolution of the LDL receptor.  Using a combination of close and distant species 
genomic sequence comparisons coupled with in vivo and in vitro studies, we show that a 
functional cholesterol-sensing sequence motif arose and was fixed within a pre-existing enhancer 
in the common ancestor of anthropoid primates. Our study demonstrates one molecular 
mechanism by which ancestral mammalian regulatory elements can evolve to perform new 
functions in the primate lineage leading to human. 
 
 
 
Introduction 
 
Since King and Wilson's provocative paper in 1975 [1], differences in gene regulatory 
sequences have been predicted to be one of the major sources of phenotypic evolution and 
divergence among animals. Consistent with this hypothesis, cis-regulatory changes have been 
found to play an important role in the evolution of morphological features in model organisms 
[2]. In contrast, evolution of physiology has been linked to changes in protein coding sequences, 
when studied in animal vision, digestive metabolism and host defense [3-7]. The contribution of 
regulatory sequence changes to the evolution of physiological differences, however, has been 
largely unexplored [8, 9]. 
 
To examine the role of cis-regulatory changes in the emergence of novel physiological 
traits in primates, we investigated the evolution of regulatory elements of the LDL receptor gene 
(LDLR), a key player in maintaining lipid homeostasis.  Cholesterol metabolism in humans has 
diverged in a variety of ways from that of many distant mammals such as rodents and dogs, with 
humans in general being more susceptible to diet-induced hypercholesterolemia [10]. The pivotal 
role of LDLR in cholesterol metabolism coupled with its known expression differences among 
mammals[11] makes it a prime candidate for investigating primate-specific evolution of 
regulatory sequences. Here we present molecular data supporting the gain of a cholesterol 
sensing DNA motif in an ancestral mammalian LDLR regulatory element at a specific stage in 
primate evolution. 
 
 
Results and Discussion 
 
Identification of primate-specific noncoding elements in the LDLR locus 
 
To identify putative primate-specific LDLR regulatory sequences, we examined 
orthologous regions from a panel of mammals closely and distantly related to human for the 
presence of evolutionarily conserved noncoding sequences using Gumby, an algorithm that 
detects sequence blocks evolving significantly more slowly than the local neutral rate (see 
Methods)[12,13, 14]. Since humans and non-human primates share many features of cholesterol 
metabolism, we specifically scanned for elements that are preferentially conserved in primates 
under the hypothesis that primate specific regulatory sequences contribute to the distinctive 
biology of those species. Pairwise sequence comparisons of the 83-kb genomic region containing 
LDLR and its entire 5’ and 3’ intergenic regions between human and each of a panel of distantly 
related species consisting of the prosimian lemur, mouse and dog, identified either the known 
promoter sequence alone (Fig. 1, Panel A and data not shown), or a limited number of noncoding 
elements (Fig. S1 and data not shown). The promoter region was the only noncoding region 
consistently identified as conserved in the three pairwise comparisons. In contrast, multiple 
sequence comparisons between human and a set of five anthropoid primate species, chosen on 
the basis of their evolutionary relationship using the “phylogenetic shadowing” strategy [15], 
identified 2 human non-coding DNA elements, named PS (primate specific) 1 and 2, that are 
very significantly conserved (P=~10-5) in primates (Fig. 1, Panel B) but undetected in 
comparisons involving human and each of the distant species (Fig. 1 and Fig. S1).  
 
  
Fig.1 Conservation profiles of the LDLR locus using close (primate) and distant 
(human-mouse) species comparisons. 
Human-mouse (A) and multiple-primate (human, baboon, colobus, dusky titi, marmoset, owl 
monkey) (B) conservation profiles were calculated using Gumby and visualized using 
RankVISTA (see Methods) and displayed with the human sequence as reference. Only ~6Kb of 
the 5’ intergenic region is shown due to incomplete primate sequence availability. The entire 3’ 
intergenic region was included in the analysis. Vertical bars depict conserved exonic (light blue) 
and non-exonic (red) sequences, with height indicating statistical significance of sequence 
conservation (see Methods). LDLR coding exons (dark blue) and UTRs (magenta) are marked 
below the conservation plots. Arrows denote the two highest-scoring primate-specific elements 
(PS1 and PS2). The inset shows the human-mouse VISTA plot for element PS2, with the 
vertical axis representing sequence identity calculated over a 100bp window.    
 
 
To independently confirm the lack of significant conservation of the PS1 and PS2 
elements between human and distant mammals, we also analyzed the human-mouse alignment 
using a sliding-window percent identity conservation criterion. We found that the human-mouse 
percent identities across PS1 and PS2 were lower than 50%(Fig. 1 and data not shown), which is 
close to the background percent identity in aligned intergenic DNA, and well below the threshold 
of 70% identity normally applied to the detection of  conserved functional sequences [16]. We 
further verified that the phastCons program [17] detects no conserved sequences overlapping 
PS1 and PS2 (data not shown). While the phastCons predictions, obtained from the UCSC 
Genome Browser, are in general based on alignment of 17 mammalian and non-mammalian 
species, conservation scores in the LDLR locus reflect only mammalian conservation, since more 
distant genomes show very limited non-exonic alignment in this locus.  
 
To quantitatively assess the conservation level of PS1 and PS2 between human and distant 
mammals, we identified the orthologous aligned counterparts of the human PS1 and PS2 
elements in lemur, mouse and dog.  Gumby analysis of conservation scores indicated that each of 
these non-anthropoid primate sequences showed a level of similarity to the human sequence 
consistent with unconstrained evolution at the neutral rate (conservation p-value, Table I). 
Together, these analyses strongly suggest the lack of significant sequence constraint between the 
anthropoid primate and mammalian PS1 and PS2 sequences. 
 
Table I. PS2 Enhancer Functional Divergence Correlates with Sequence 
Constraint. Conservation p-values are calculated using Gumby [12] under the null 
hypothesis of evolution at the neutral (background) rate. Low p-values indicate that the null 
model of neutrality should be rejected, with the lowest p-values identify the most significantly 
conserved sequences. The sequences analyzed for human-mammal conservation or enhancer 
activity correspond to the Gumby predicted conserved sequence and approximately 200bp of 
flanking sequence on either side (See Methods). Enhancer strength is shown as fold increase 
over promoter alone in luciferase assays in 293T cells. 
 
ND: Not done.  
 
 
The human LDLR PS2 element shows significantly higher enhancer activity than its 
mammalian orthologs 
 
To explore the potential regulatory function of these two primate-specific conserved 
elements, we examined their ability to drive reporter gene expression in both a transient 
transfection assay in human 293T cells and an in vivo mouse liver gene transfer assay [18].  Each 
human element plus approximately 200bp of flanking sequence on either side was cloned 
upstream of the human LDLR promoter fused to a luciferase reporter gene. Human element PS2, 
but not PS1, consistently increased luciferase expression approximately 5-fold relative to the 
human promoter alone in both the in vitro and in vivo assays (Fig. 2). Enhancer activity of this 
element was further confirmed by the finding that genomic region corresponding to PS2, but not 
PS1, is a DNase I hypersensitive site in human liver cells (Fig S2 and data not shown).  
 
 
Fig. 2 The human LDLR PS2 enhancer shows significantly higher activity than the 
orthologous lemur, mouse and dog enhancers. Luciferase assay analysis of (A) 
transient transfections into human 293T cells and (B) plasmid DNA transfer into mouse liver. 
The luciferase reporter constructs tested are either the LDLR promoter alone (promoter), or the 
promoter in combination with the LDLR PS2 enhancer from one of the indicated species. Error 
bars indicate standard deviation. “SRE mutant” refers to the mutagenized human SRE with 4 
point substitutions relative to the wild-type (WT) SRE (Fig. 4A). Luciferase activity is reported in 
arbitrary units. Each triangle in (B) represents luciferase activity in an individual mouse. Red 
bars denote the median activity of each construct.  
 
 
To explore the regulatory function, if any, of mammalian sequences orthologous to human 
PS2, we cloned the PS2-aligned sequences from lemur, mouse and dog into the luciferase 
reporter vector described above and compared their activity to that of the human sequence. 
Despite the lack of statistically significant sequence constraint between the human enhancer and 
its lemur, mouse and dog orthologs, the latter three sequences exhibited enhancer activity both in 
vitro and in vivo (Fig. 2). The human regulatory element, however, consistently exhibited 
stronger enhancer activity in both assays, driving two-fold greater expression than lemur or dog 
PS2, and four-fold greater expression than mouse (Fig. 2A). This observation, coupled with the 
evidence of negative selection acting on the primate enhancer and the lack of significant 
sequence constraint between the anthropoid primate and mammalian PS2 sequences 
(conservation p-value, Table I), suggests that the stronger enhancer activity in human is a gain of 
function in the anthropoid primate lineage with a potentially important adaptive role in these 
species. 
 
 
An anthropoid-primate specific sterol regulatory element (SRE) contributes to distinct 
human PS2 enhancer activity 
 
To identify the molecular basis of the primate-specific activity of PS2, we 
computationally dissected the 860-bp human PS2 enhancer (see Methods) and found a sterol 
regulatory element (SRE), a binding site specifically recognized by the cholesterol sensing 
proteins SREBP (sterol regulatory element binding protein) which are known to play a key role 
in the regulation of LDLR [19, 20]. Phylogenetic analysis of the orthologous PS2 sequences from 
3 distant mammals (mouse, rat and dog), 3 prosimians (lemur, mouse lemur and galago), and 9 
anthropoid primates covering all major lineages including hominoids, old-world and new-world 
monkeys revealed the presence of the SRE exclusively in anthropoid primates (Fig 3). This 
phylogenetic distribution of the SRE in mammals can be most parsimoniously explained by the 
appearance of the SRE in the ancestor of anthropoid primates after its divergence from 
prosimians (Fig 3).  
 
The functional role of the binding motif identified by computational analysis was 
explored by site-specific mutagenesis. A 4-bp substitution was introduced into the SRE, which 
was expected to completely inactivate the site based on a previously reported mutagenesis study 
[21]. The 4-bp substitution in the SRE decreased human enhancer activity in the human cell 
culture assay and the in vivo mouse liver DNA transfer assay to a level comparable to that of the 
lemur, mouse and dog enhancers, species which lack a computationally predicted SRE (Fig. 2). 
The functionality of the SRE, found exclusively in anthropoid primates, suggests that this 
element is likely to contribute to the stronger activity found in these species. We also identified 
within the 860-bp enhancer a 21-bp subregion that shows strong conservation across mammalian 
species including lemur, mouse lemur, galago, mouse and dog and contains predicted binding 
sites for transcription factors AP-4 and AP-1. Deletion of the conserved 21-bp sequence from 
either human or dog PS2 resulted in a significant reduction in enhancer activity (data not shown), 
suggesting that the evolutionarily conserved AP-4 and AP-1 sites are important for the core 
enhancer activity shared among mammals. It is worth noting that such short blocks of genuinely 
constrained sequence are not easily distinguishable from the numerous “coincidentally 
conserved” sequence fragments that are likely to occur in large genomic regions as a 
consequence of stochastic variation in the incidence of neutral mutations. Incorporation of 
additional information, namely the binding specificities of transcription factors, was required to 
classify this 21-bp fragment as a functional candidate. Thus, conservation of this short 
subsequence in multiple mammals does not detract from the fact that the enhancer sequence is 
significantly conserved only in anthropoid primates, as described above.  
  
 
  
Fig. 3 Phylogenetic analysis of the sterol regulatory element (SRE). The human SRE 
motif and its orthologs were scored for transcription-factor binding affinity, with low motif scores 
indicating low predicted affinity to SREBP (see Methods). Since the SRE is present in all the 
analyzed anthropoid primates (indicated by the red branches in the tree) and absent from the 
prosimians, rodents and dog, emergence in the lineage leading to anthropoid primates is the 
most parsimonious explanation.  
 
 
Since SREBP-2, the major regulator of LDLR [19, 20] specifically binds to the SRE [11], 
we examined the responsiveness of the human, lemur, mouse and dog orthologous PS2 
enhancers to this transcription factor. Co-transfection of the reporter gene driven by PS2 and the 
human LDLR promoter with a construct expressing the mature form of SREBP-2 indicated that 
the human enhancer was strongly activated by the exogenous SREBP-2, to a level 5-fold higher 
than that of the human LDLR promoter alone, which is known to be SREBP-responsive as well 
[22]. The lemur, mouse and dog enhancers were activated to a significantly lesser extent, 
consistent with their much lower SRE prediction score and with their lack of additional 
consensus SRE motifs within the PS2 element (Fig. 3, Fig. 4A and data not shown).  To 
determine whether the observed differential SREBP-2 response among tested mammalian PS2 
enhancers was directly mediated by the predicted SRE, we inactivated or restored the consensus 
SRE by site-specific mutagenesis at the orthologous positions of the human and dog PS2 
element, respectively. Substituting 4 bases in the human SRE motif, which reduced the motif 
matrix score from 1 to 0.35 (see Methods), resulted in a reduction in SREBP-2 enhancer 
response to a level comparable to that of the lemur, mouse and dog enhancers. These results 
indicate that the anthropoid-specific SRE mediates the activation of the PS2 enhancer by 
SREBP-2 and contributes to the strong enhancer activity characterizing human and other 
anthropoid primates. Furthermore, substituting 3 bases in the dog SRE, so as to increase the SRE 
motif score from 0.47 to 1 (representing a perfect SRE), led to a significant increase in the dog 
enhancer response to SREBP-2, though only to half the level of the human PS2 enhancer (Fig. 
4B). This suggests that the anthropoid primate-specific SRE is part of a combinatorial 
mechanism [23], including possible additional substitutions in the core enhancer element, that 
contribute to the stronger human PS2 enhancer activity.  
 
 
Fig. 4 Relation between SRE motif score and response of PS2 enhancer to 
SREBP-2. (A) Alignment of sequences from indicated species at position orthologous to 
human PS2 sterol regulatory element (SRE). “Human mutant” refers to the mutated human SRE 
with 4 point substitutions relative to the human wild-type. “Dog mutant” refers to the consensus 
SRE introduced into dog PS2 by means of 3 point substitutions. (B) Luciferase assay analysis of 
reporter construct and the SREBP-2 expression vector cotransfection into 293T cells. The LDLR 
PS2 element from each of the indicated species was tested in combination with the LDLR 
promoter.  The Y-axis denotes SRE motif score (likeness to known SRE motifs, see Methods). 
Response of the PS2 element to SREBP-2 is shown as the increase in luciferase expression 
level (arbitrary units) upon activation by 3 ng of SREBP-2 expression vector. Expression level 
increase for LDLR promoter alone is indicated by the dotted line. Error bars indicate standard 
deviation. 
 
 
The role of SREBP-2 in regulating the human PS2 enhancer was further explored in its 
native chromosomal context in HepG2 cells, which actively express SREBP-2 and are a well-
defined system for studying LDLR regulation [24-26]. Our analysis showed that the PS2 
sequence is a DNaseI hypersensitive site in HepG2 cells (see Supplementary Information Fig. 
S2), suggesting that the corresponding DNA element is involved in transcriptional regulation of 
the endogenous gene. Using the ChIP (chromatin immunoprecipitation) assay, we were able to 
show that fractionation of chromatin with an anti-SREBP-2 antibody specifically enriched for 
endogenous PS2 and LDLR promoter DNA relative to control region (Fig. 5); the latter has 
previously been shown to be bound by SREBP-2 [27].Together, the DNAse I hypersensitivity 
and ChIP assays provide strong evidence that SREBP-2 binds in the vicinity of the human PS2 
enhancer in its native genomic locus. Regulation of the enhancer by SREBP-2 also suggests that 
the PS2 element plays a role in the activation of its upstream gene LDLR rather than the 
downstream gene Spbc24, which encodes a component of the kinetochore Ndc80 protein 
complex [28]. It has recently been noted based on genome -wide analysis of gene expression that 
SREBP targets are largely restricted to lipid-metabolism genes, including LDLR [19]. No 
connection was found between SREBP and kinetochore structural genes such as Spbc24.  
 
 
Fig. 5 Anti-SREBP-2 antibody specifically enriches the human PS2 DNA 
sequences in HepG2 cells in a ChIP assay. DNA precipitates were measured by real-
time PCR using primers spanning the indicated regions. Control region (control) corresponds to 
the first coding exon of the neighboring gene SPBC24, which is approximately 7.5 kb away from 
the PS2 sequence. The results are presented as fold increase in the enrichment of precipitated 
DNA by anti-SREBP-2 antibody over non-specific IgG. Graphical representations of the mean ± 
SE from three independent experiments are shown. 
 
 
Conclusion 
 
We have shown phylogenetic and molecular data supporting the evolution of differential 
gene expression of LDLR in mammals. Transcriptional control of LDLR is mainly effected 
through the intracellular cholesterol sensor SREBP-2, which mediates the increased transcription 
of LDLR and other cholesterol synthesis genes in response to low cholesterol levels [22]. The 
differential response among mammals of the PS2 enhancer to SREBP-2 suggests that species-
specific regulation of LDLR is expected in conditions that result in decreased intracellular 
cholesterol levels, such as reduced availability of dietary cholesterol, and has implications for the 
study of LDLR response to cholesterol lowering drugs in animal models.  
 
While the human LDLR coding sequence and promoter are well conserved in all 
sequenced mammals (Fig.1 and Fig. S1), our data support the modification of the expression 
characteristics of this gene through the primate-specific evolution of a distal regulatory element.  
We have shown the emergence and fixation of a sterol-responsive element (SRE) in the common 
ancestor of anthropoid primates, which modifies the expression driven by a pre-existing 
mammalian enhancer shared by all tested mammals.  This demonstrates one mechanism by 
which mammalian regulatory elements can evolve to perform new functions. Given the vital 
importance of LDLR in energy storage, the appearance of a new cholesterol sensing element in 
the LDLR enhancer may have played a role in the evolution of new physiological features, as the 
ancestor of anthropoid primates adapted to different metabolic requirements and diets. 
Materials and Methods 
 
Plasmid constructs.  
The human LDLR promoter was cloned in the proper orientation upstream of the luciferase 
cDNA in the pGL3Basic construct (Promega). The human PS1 element and the PS2 elements 
from the human, lemur, mouse, and dog LDLR loci were PCR cloned into polylinker sites in the  
(-) orientation upstream of the promoter. The cloned human PS1 element corresponds to the 
Gumby predicted conserved sequence and approximately 200bp of flanking sequence on either 
side (hg18, chr19:11067913-11068639). To clone the human PS2 element, the region containing 
human PS2 was PCR cloned into pGL3Basic (see Supplementary Information Table 1 for primer 
sequences), and digested with Spe I and Nhe I to only include the Gumby predicted conserved 
sequence and approximately 200bp of flanking sequence on either side (hg18, chr19:11110333-
11111194). Site-specific point mutations and deletions were introduced into human and dog PS2 
elements using QuikChangeII site-directed mutagenesis kit (Stratagene) according to 
manufacturer’s protocol and were confirmed by sequencing. The expression construct for human 
mature form of SREBP-2 (pcDNA.2FLAG SREBP-2) was kindly provided by Dr. Timothy F. 
Osborne (UC Irvine). 
 
Transient-transfection reporter assay.  
293T cells (ATCC CRL-11268), a human embryonic kidney cell line, were grown at 37°C and 
5% CO2 in Dulbecco’s modified Eagle’s medium (ATCC), supplemented with 10% FBS 
(Hyclone), L-glutamine, penicillin-streptomycin. Cells with a passage number below 15 were 
used.  The cells were grown in 12 well plates (4x104 cells/well) and transfected using Fugene 
(Roche Molecular Biochemicals) following the manufacturer’s protocol.  Briefly, 100 ng of each 
assayed plasmid and 10 ng pCMVβ (BD Biosciences) were mixed with 1.5 µl Fugene and added 
to each well.  Following 42-48 hours of incubation cells were harvested and lysed. Activity of 
luciferase and β-Galactosidase was measured using the Luciferase Assay System (Promega) and 
the Galacto-Light Plus (Applied Biosystems) respectively. Luciferase activity for each sample 
was normalized to the β-galactosidase assay control. For cotransfection experiments, 100 ng of 
the lulciferase reporter gene construct, 3 ng of SREBP-2 expression vector, and 10 ng of pCMVβ 
were used. Transfections were carried out in duplicates. All experiments are representative of at 
least three independent transfections. 
 
Tail vein plasmid DNA transfer assays  
Tail vein injection was performed as described by Herweijer and Wolff [18] following the 
TransIT® In Vivo Gene Delivery System Protocol (Mirus Corporation). Six to nine FVB male 
mice (Charles River Laboratory) at age 7-8 weeks were used for each reporter gene construct. 
Ten µg of each reporter construct, along with 2 µg of pCMVβ(BD Biosciences) to correct for 
delivery efficiency, were injected into each mouse. The entire content of the syringe was 
delivered in 3-5 seconds. Animals were sacrificed 24 hours later, livers extracted, measured to 
correct for size, homogenized, and centrifuged for 15 minutes at 4°C, 14,000 rpm. Activity of 
luciferase and β-Galactosidase was measured as described above.  All p-values are from the two-
sample Wilcoxon rank-sum (Mann-Whitney) test using STATA (STATA Corporation). All 
experimental results are representative of two independent plasmid DNA transfer assays.  
 
Chromatin immunoprecipitation 
HepG2 cells (ATCC HB-8065) were cultured in DMSF (Defined medium serum free) medium 
for 24 hours for induction of endogenous SREBPs[29]. Chromatin immunoprecipitaion assays 
were performed as described[30]. Crosslinked chromatin was immunoprecipitated with a specific 
SREBP-2 antibody (Santa Cruz sc-8151)[27] or IgG control.  
 
Sources of sequence data 
Draft sequences of baboon, colobus, dusky titi, marmoset, owl monkey, lemur and galago BACs 
were determined by sequencing ends of 3 Kb subclones to 8-10-fold coverage using BigDye 
terminators (Applied Biosystems) and assembling reads into contigs with the Phred-Phrap-
Consed suite as described previously[31].  All BAC sequences were submitted to GenBank with 
the following species and accession numbers:  baboon (Papio hamadryas), AC140974; colobus 
(Colobus guereza), AC150433; marmoset (Callithrix jacchus), AC145530; dusky titi (Callicebus 
moloch), AC144655; owl monkey (Aotus hybrid), AC171393; squirrel monkey (Saimiri 
boliviensis boliviensis), AC146467;lemur (lemur catta), AC118569; mouse lemur (microcebus 
murinus), AC175656; Galago (otolemur garnetti), AC175655).  Human, chimpanzee, rhesus, 
mouse, rat and dog sequences were downloaded from the UCSC Genome Bioinformatics website 
(http://genome.ucsc.edu). 
 
Analysis of sequence conservation 
We aligned the human LDLR locus (chr19:11,055,219-11,117,169; NCBI Build 35) to its 
orthologs in baboon, colobus, dusky titi, marmoset, owl monkey, lemur, mouse and dog using 
MLAGAN[32]. Due to incomplete primate sequence availability, we included only ~6 kb of the 
5' intergenic region in the analysis. Aligned sequences were scanned for statistically significant 
evolutionarily conserved regions using Gumby  [12] [13] [14]. Gumby goes through the 
following three-step process to identify statistically significant conservation in the global 
alignment input. (i) Non-coding regions in the alignment are used to estimate the local neutral 
mismatch rates among all pairs of aligned sequences. The rates are used to derive a log-
likelihood scoring scheme for slow versus neutral evolution, where the slow rate is set to some 
fraction (in this case, half) of the neutral rate. (ii) Each alignment position is then assigned a 
conservation score using a phylogenetically weighted sum-of-pairs scheme. (iii) Conserved 
regions of any length are identified as alignment blocks with a high cumulative conservation 
score and assigned p-values using Karlin-Altschul statistics [33]. We set a threshold p-value of 
0.1 in a baseline human sequence length of 10 kb. Conserved regions identified by Gumby were 
visualized using RankVISTA. In addition, human-mouse sequence conservation was analysed 
using the VISTA web server [34], with the standard criteria of 70% sequence identity in window 
of size 100 bp. 
 
Binding-site prediction 
We scanned the aligned enhancer sequences for predicted transcription-factor binding sites using 
DiAlign TF (http://www.genomatix.de, Genomatix Software GmbH). Anthropoid primate 
(human, baboon, colobus, dusky titi, marmoset and owl monkey) sequences were assessed for 
the presence of sites conserved across all six species that were predicted to bind one of the 
following liver-expressed transcription factors: C/EBP, LXR, FXR, COUP-TF, PPAR, HNF1, 
HNF3, HNF4 and SREBP.  Binding sites common to primates and mammals were predicted on 
the basis of conservation of any vertebrate transcription factor motif in at least 8 of the 10 
analysed species (6 anthropoid primates, lemur, mouse, rat and dog). Motif scores of the SREs or 
SRE orthologs of individual species were calculated using rVISTA [35], and normalized so that 
the maximum achievable score is 1.0, and the expected score of a random nucleotide sequence 
with the local GC content is zero. The score distribution of functional SREs was calculated from 
the binding profile of SREBP (http://www.gene-regulation.com/pub/databases.html), assuming 
that nucleotide frequencies at each position in the motif are independent. We retrospectively 
augmented the species set with SRE orthologs from chimpanzee, rhesus, squirrel monkey, mouse 
lemur and galago, based on pairwise alignments of those species to human. 
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Supplemental Data:  
 
 
Fig. S1 Conservation profiles of the LDLR locus using human-dog (A) and human-
lemur (B) sequence comparisons.  Conservation profiles were obtained using RankVISTA 
and displayed with the human sequence as reference as described in Fig. 1. 
 
 
 
 
 
 
 
 
 
 
Fig. S2  DNaseI hypersensitive site mapping around LDLR PS2 region in human 
liver cell line HepG2. Vertical arrows indicate lanes with internal size markers that were 
generated by enzyme digestion of the LDLR_PS2 sequence (lane 1) and a position 
approximately 90bp downstream of the element (lane 2). Horizontal arrow points to the 
hypersensitive site (HS). Co-migration of the internal size marker 1 with the HS localizes the HS 
to LDLR PS2 sequence.  
 
A total of two tables listing all relevant primer sequences used. 
 
Table 1: Primers used in the cloning of human LDLR promoter and PS2 elements 
from indicated species. 
Element ID                                                 Primers 
 
Human F: ATGCGTTTCCAATTTTGAGG 
LDLR promoter R: TCTAGCAGGGGGAGGAGTTT 
 
Human PS1                F: AGCCTCAGTCATGCCACTG 
                         R: GGCCTAGGCAACATACCAAG 
 
Human PS2 F: GGAGGCCACTGTGTCAGTTT 
 R: ACTCCAGCCTGGGAAACTCT 
 
Lemur PS2 F: ATCCCCAGCTGGTATCCTCT 
 
 
R: ACAGCTGGTTTCACAGCATT 
Mouse PS2 F: GCAGCAGCTGATTTCTGACA 
 R: AGGCATGCTTGTGAGAGGTA 
 
Dog PS2 F: TTGGTACCCCCAACTCTGTC 
 R: CAGAGCCAGGATTTGACCTG 
 
HumanPS2 21-bp deletion: CATCCCAGACCACCTGGAGCCTCTG 
 
DogPS2 21-bp deletion: GGCGGCCCAAACGCTGGAGCCTGC 
 
HumanPS2 SRE mutant: GTCCCTGGTCCCCAGAACCAAACTGAGCATGGCCGC
 
DogPS2 SRE mutant: GCCCTGGGCACATCACCCCACCCCGAGCGGGGC 
 
 
 
Table 2: primers used in ChIP assay 
    Region                                 Primers 
 
Human PS2 F: TCTGAGTGGGAGTCCCTGGT 
 R: GAAAGTTGCCAGGAAACCCC 
 
Human F: AATGACGTGGGCCCCG 
LDLR promoter R: ACCTGCTGTGTCCTAGCTGGA 
 
Control F: TGATGAATTTCCTGGAGAGCTG 
 R: TCCATCATGGCCCCAGTG 
 
